These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 28268108)

  • 21. The United States StuDy for EvalUating EndovasculaR TreAtments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By usIng the Protégé EverfLex NitInol STent SYstem II (DURABILITY II).
    Matsumura JS; Yamanouchi D; Goldstein JA; Pollock CW; Bosiers M; Schultz GA; Scheinert D; Rocha-Singh KJ
    J Vasc Surg; 2013 Jul; 58(1):73-83.e1. PubMed ID: 23642924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 1-Year Results of the ZEPHYR Registry (Zilver PTX for the Femoral Artery and Proximal Popliteal Artery): Predictors of Restenosis.
    Iida O; Takahara M; Soga Y; Nakano M; Yamauchi Y; Zen K; Kawasaki D; Nanto S; Yokoi H; Uematsu M;
    JACC Cardiovasc Interv; 2015 Jul; 8(8):1105-1112. PubMed ID: 26117463
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vascular elastography: a novel method to characterize occluded lower limb arteries prior to endovascular therapy.
    Takimura H; Hirano K; Muramatsu T; Tsukahara R; Ito Y; Sakai T; Ishimori H; Nakano M; Yamawaki M; Araki M; Kato T; Kobayashi N; Sakamoto Y; Ishii A; Takama T; Tokuda T
    J Endovasc Ther; 2014 Oct; 21(5):654-61. PubMed ID: 25290793
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Angiographic Dissection Patterns and Patency Outcomes After Balloon Angioplasty for Superficial Femoral Artery Disease.
    Fujihara M; Takahara M; Sasaki S; Nanto K; Utsunomiya M; Iida O; Yokoi Y
    J Endovasc Ther; 2017 Jun; 24(3):367-375. PubMed ID: 28351208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug-Eluting Stent vs Percutaneous Transluminal Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis: Results From a Retrospective 1-Year Multicenter Study.
    Murata N; Takahara M; Soga Y; Nakano M; Yamauchi Y; Zen K; Kawasaki D; Yokoi H; Tosaka A; Tanaka N; Iida O
    J Endovasc Ther; 2016 Aug; 23(4):642-7. PubMed ID: 27099284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-World Performance of Paclitaxel Drug-Eluting Bare Metal Stenting (Zilver PTX) for the Treatment of Femoropopliteal Occlusive Disease.
    Tran K; Ullery BW; Kret MR; Lee JT
    Ann Vasc Surg; 2017 Jan; 38():90-98. PubMed ID: 27554688
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravascular Ultrasound-Derived Stent Dimensions as Predictors of Angiographic Restenosis Following Nitinol Stent Implantation in the Superficial Femoral Artery.
    Miki K; Fujii K; Kawasaki D; Shibuya M; Fukunaga M; Imanaka T; Tamaru H; Sumiyoshi A; Nishimura M; Horimatsu T; Saita T; Okada K; Kimura T; Honda Y; Fitzgerald PJ; Masuyama T; Ishihara M
    J Endovasc Ther; 2016 Jun; 23(3):424-32. PubMed ID: 27044270
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Classification and clinical impact of restenosis after femoropopliteal stenting.
    Tosaka A; Soga Y; Iida O; Ishihara T; Hirano K; Suzuki K; Yokoi H; Nanto S; Nobuyoshi M
    J Am Coll Cardiol; 2012 Jan; 59(1):16-23. PubMed ID: 22192663
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence, predictors, and prognosis of in-stent occlusion after endovascular treatment with nitinol stents for femoropopliteal lesions.
    Dohi T; Iida O; Soga Y; Hirano K; Suzuki K; Takahara M; Uematsu M; Nanto S
    J Vasc Surg; 2014 Apr; 59(4):1009-1015.e1. PubMed ID: 24360237
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of Vascular Calcifications on Long Femoropopliteal Stenting Outcomes.
    Kaladji A; Vent PA; Danvin A; Chaillou P; Costargent A; Guyomarch B; Quillard T; Gouëffic Y
    Ann Vasc Surg; 2018 Feb; 47():170-178. PubMed ID: 28893701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of Clinical Outcomes between Endovascular Therapy with Self-Expandable Nitinol Stent and Femoral-Popliteal Bypass for Trans-Atlantic Inter-Society Consensus II C and D Femoropopliteal Lesions.
    Okuno S; Iida O; Iida T; Takahara M; Yamaoka T; Kitano I; Asai M; Masuda M; Okamoto S; Ishihara T; Nanto K; Kanda T; Tsujimura T; Matsuda Y; Mano T
    Ann Vasc Surg; 2019 May; 57():137-143. PubMed ID: 30500627
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A single center experience of Zilver PTX for femoro-popliteal lesions.
    Kang WY; Campia U; Didier RJ; Kiramijyan S; Koifman E; Negi SI; Lipinski MJ; Baker NC; Escarcega RO; Torguson R; Waksman R; Bernardo NL
    Cardiovasc Revasc Med; 2016 Sep; 17(6):399-403. PubMed ID: 27496591
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of antiplatelet/anticoagulation regimens after Viabahn stent graft treatment for femoropopliteal occlusive disease.
    Ullery BW; Tran K; Itoga N; Casey K; Dalman RL; Lee JT
    J Vasc Surg; 2015 Jun; 61(6):1479-88. PubMed ID: 25704407
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of the femoropopliteal artery with the bioresorbable REMEDY stent.
    Bontinck J; Goverde P; Schroë H; Hendriks J; Maene L; Vermassen F
    J Vasc Surg; 2016 Nov; 64(5):1311-1319. PubMed ID: 27462002
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The prognostic value of the serum eicosapentaenoic acid to arachidonic acid ratio in relation to clinical outcomes after endovascular therapy in patients with peripheral artery disease caused by femoropopliteal artery lesions.
    Hishikari K; Kimura S; Yamakami Y; Kojima K; Sagawa Y; Otani H; Sugiyama T; Kuwahara T; Hikita H; Takahashi A; Isobe M
    Atherosclerosis; 2015 Apr; 239(2):583-8. PubMed ID: 25733330
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug-eluting stenting for femoropopliteal lesions, followed by cilostazol treatment, reduces stent restenosis in patients with symptomatic peripheral artery disease.
    Zen K; Takahara M; Iida O; Soga Y; Kawasaki D; Nanto S; Yokoi H; Matoba S;
    J Vasc Surg; 2017 Mar; 65(3):720-725. PubMed ID: 28073668
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Restenosis after stent implantation for superficial femoral artery disease in patients treated with cilostazol.
    Soga Y; Iida O; Hirano K; Suzuki K; Yokoi H; Nobuyoshi M
    Catheter Cardiovasc Interv; 2012 Mar; 79(4):541-8. PubMed ID: 21805619
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lumen Gain After Endovascular Therapy in Calcified Superficial Femoral Artery Occlusive Disease Assessed by Intravascular Ultrasound (CODE Study).
    Fujihara M; Kozuki A; Tsubakimoto Y; Takahara M; Shintani Y; Fukunaga M; Iwasaki Y; Nakama T; Yokoi Y
    J Endovasc Ther; 2019 Jun; 26(3):322-330. PubMed ID: 30873909
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Five-year prognosis after endovascular therapy in claudicant patients with iliofemoral artery disease.
    Miura T; Soga Y; Miyashita Y; Iida O; Kawasaki D; Hirano K; Suzuki K; Ikeda U
    J Endovasc Ther; 2014 Jun; 21(3):381-8. PubMed ID: 24915585
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of restenosis in the use of helical interwoven nitinol stents to treat femoropopliteal occlusive disease.
    Chan YC; Cheng SW; Cheung GC
    J Vasc Surg; 2015 Nov; 62(5):1201-9. PubMed ID: 26169015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.